Stockhead Presents: Vital Signs https://stockhead.com.au en Stockhead's Health and Biotech reporter Nadine McGrath is joined by industry experts to discuss healthcare and biotechnology investments. Hear insights from leaders, innovators, and investors who are shaping the future of healthcare. Whether you're an investor looking for the next big opportunity, a professional in the field, or simply curious about the advancements transforming healthcare, Vital Signs provides valuable insights and fascinating information. Hear about cutting-edge technologies, groundbreaking research, and the financial strategies driving success in the biotech world. Subscribe now to be a part of the exciting landscape of health and biotech investment. https://megaphone.imgix.net/podcasts/369681e6-3f27-11ef-815f-57ced01981c0/image/447eea5a55ee6e1f94cd21042046aec8.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress Stockhead Presents: Vital Signs https://stockhead.com.au no episodic Your guide to investing in a healthier future Stockhead Stockhead's Health and Biotech reporter Nadine McGrath is joined by industry experts to discuss healthcare and biotechnology investments. Hear insights from leaders, innovators, and investors who are shaping the future of healthcare. Whether you're an investor looking for the next big opportunity, a professional in the field, or simply curious about the advancements transforming healthcare, Vital Signs provides valuable insights and fascinating information. Hear about cutting-edge technologies, groundbreaking research, and the financial strategies driving success in the biotech world. Subscribe now to be a part of the exciting landscape of health and biotech investment. Stockhead's Health and Biotech reporter Nadine McGrath is joined by industry experts to discuss healthcare and biotechnology investments.

Hear insights from leaders, innovators, and investors who are shaping the future of healthcare.

Whether you're an investor looking for the next big opportunity, a professional in the field, or simply curious about the advancements transforming healthcare, Vital Signs provides valuable insights and fascinating information.

Hear about cutting-edge technologies, groundbreaking research, and the financial strategies driving success in the biotech world.

Subscribe now to be a part of the exciting landscape of health and biotech investment.

]]> Stockhead content@stockhead.com.au Inside Prescient Therapeutics' fight against a rare blood cancer Stockhead's Vital Signs sits down with Prescient Therapeutics (ASX:PTX) CEO James McDonnell to unpack PTX-100, a first-in-class cancer therapy targeting the RAS pathway implicated in 22% of cancers. From the science behind the drug to its phase two trial in cutaneous T-cell lymphoma, a $580 million validating licensing deal, and the milestones ahead, McDonnell breaks down what investors should be watching next. Learn more about your ad choices. Visit megaphone.fm/adchoices Fri, 28 Aug 2026 04:54:00 -0000 full Stockhead Stockhead's Vital Signs sits down with Prescient Therapeutics (ASX:PTX) CEO James McDonnell to unpack PTX-100, a first-in-class cancer therapy targeting the RAS pathway implicated in 22% of cancers. From the science behind the drug to its phase two trial in cutaneous T-cell lymphoma, a $580 million validating licensing deal, and the milestones ahead, McDonnell breaks down what investors should be watching next. Learn more about your ad choices. Visit megaphone.fm/adchoices Stockhead's Vital Signs sits down with Prescient Therapeutics (ASX:PTX) CEO James McDonnell to unpack PTX-100, a first-in-class cancer therapy targeting the RAS pathway implicated in 22% of cancers.

From the science behind the drug to its phase two trial in cutaneous T-cell lymphoma, a $580 million validating licensing deal, and the milestones ahead, McDonnell breaks down what investors should be watching next.


Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1047 MASTRR study redefining regenerative healing - Aroa Biosurgery (ASX:ARX) In today's episode, Nadine speaks to Dr. Adam Young of Aroa Biosurgery (ASX:ARX) Learn more about your ad choices. Visit megaphone.fm/adchoices Mon, 09 Mar 2026 19:00:00 -0000 full Stockhead In today's episode, Nadine speaks to Dr. Adam Young of Aroa Biosurgery (ASX:ARX) Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Dr. Adam Young of Aroa Biosurgery (ASX:ARX)

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1423 Vital Signs Podcast: Health Food Symmetry In today's episode, Nadine speaks to Gordon Edwards, CEO of Health Food Symmetry Learn more about your ad choices. Visit megaphone.fm/adchoices Mon, 09 Mar 2026 05:04:00 -0000 full Stockhead In today's episode, Nadine speaks to Gordon Edwards, CEO of Health Food Symmetry Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Gordon Edwards, CEO of Health Food Symmetry

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 716 Redefining hearing health with personalised sound technology-Audeara (ASX:AUA) In today's episode, Nadine speaks to Dr. James Fielding, CEO of Audeara (ASX:AUA) Learn more about your ad choices. Visit megaphone.fm/adchoices Tue, 21 Oct 2025 19:00:00 -0000 full Stockhead In today's episode, Nadine speaks to Dr. James Fielding, CEO of Audeara (ASX:AUA) Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Dr. James Fielding, CEO of Audeara (ASX:AUA)

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1720 Prescient eyes FDA fast track for cancer drug treatment | Prescient Therapeutics (ASX:PTX) In today's episode, Nadine speaks to James McDonnell, CEO of Prescient Therapeutics (ASX:PTX) Learn more about your ad choices. Visit megaphone.fm/adchoices Tue, 01 Jul 2025 19:00:00 -0000 full Stockhead In today's episode, Nadine speaks to James McDonnell, CEO of Prescient Therapeutics (ASX:PTX) Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to James McDonnell, CEO of Prescient Therapeutics (ASX:PTX)

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1033 Heartfelt & WiSE: EBR embarks on new growth chapter after US FDA approval In today's episode, Nadine speaks to John McCutcheon President & CEO of EBR Systems (ASX:EBR) Learn more about your ad choices. Visit megaphone.fm/adchoices Sun, 15 Jun 2025 23:39:00 -0000 full Stockhead In today's episode, Nadine speaks to John McCutcheon President & CEO of EBR Systems (ASX:EBR) Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to John McCutcheon President & CEO of EBR Systems (ASX:EBR)

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1146 Breakthrough brain scanning technology overcoming diagnostic hurdles - Compumedics (ASX:CMP) In today's episode, Nadine speaks to Gordon Haid, Global Neuro-Imaging Business Director  of Compumedics (ASX:CMP) Learn more about your ad choices. Visit megaphone.fm/adchoices Thu, 29 May 2025 16:00:00 -0000 full Stockhead In today's episode, Nadine speaks to Gordon Haid, Global Neuro-Imaging Business Director  of Compumedics (ASX:CMP) Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Gordon Haid, Global Neuro-Imaging Business Director  of Compumedics (ASX:CMP)

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 927 no Clever Culture Systems' shift to big pharma clients is perfect prescription - Clever Culture Systems (ASX:CC5) In today's episode, Nadine speaks to Brent Barnes, CEO and Managing Director of Clever Culture Systems (ASX:CC5) Learn more about your ad choices. Visit megaphone.fm/adchoices Tue, 25 Mar 2025 19:00:00 -0000 full Stockhead In today's episode, Nadine speaks to Brent Barnes, CEO and Managing Director of Clever Culture Systems (ASX:CC5) Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Brent Barnes,

CEO and Managing Director of Clever Culture Systems (ASX:CC5)

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1167 Pioneering Pathology's Digital Future - Optiscan (ASX:OIL) In today's episode, Nadine speaks to Dr Camile Farah, CEO of Optiscan (ASX:OIL) Learn more about your ad choices. Visit megaphone.fm/adchoices Thu, 27 Feb 2025 19:00:00 -0000 full Stockhead In today's episode, Nadine speaks to Dr Camile Farah, CEO of Optiscan (ASX:OIL) Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Dr Camile Farah, CEO of Optiscan (ASX:OIL)

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1407 "A global giant recognised our innovation" - Wellnex Life (ASX:WNX) In today's episode, Nadine speaks to Zack Bozinovski, Executive Director of Wellnex Life (ASX:WNX). Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 05 Feb 2025 16:00:00 -0000 full Stockhead In today's episode, Nadine speaks to Zack Bozinovski, Executive Director of Wellnex Life (ASX:WNX). Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Zack Bozinovski, Executive Director of Wellnex Life (ASX:WNX).

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 950 "Unlocking regenerative medicine for everybody" - Aroa Biosurgery (ASX:ARX) In today's episode, Nadine speaks to Dr. Adam Young, Vice President of Medical Affairs at Aroa Biosurgery (ASX:ARX). Learn more about your ad choices. Visit megaphone.fm/adchoices Tue, 14 Jan 2025 19:00:00 -0000 full Stockhead In today's episode, Nadine speaks to Dr. Adam Young, Vice President of Medical Affairs at Aroa Biosurgery (ASX:ARX). Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Dr. Adam Young, Vice President of Medical Affairs at Aroa Biosurgery (ASX:ARX).

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 929 "We want to become a dominant figure in wound care" - Aroa Biosurgery (ASX:ARX) | Vital Signs In today's episode, Nadine speaks to James Agnew, CFO of Aroa Biosurgery (ASX:ARX) to discuss New Zealand's history of medical advancements and how Aroa is looking to become a world leader in wound care. After listing in 2020, Aroa is building from the original discoveries made by Dr. Brian Ward, using the forestomach of sheep to create a tissue scaffold assisting with chronic wound care, hernia repair and breast reconstruction among other conditions. James also gives us details on the company's current financial position and what the next 3-5 years looks like for growth. Learn more about your ad choices. Visit megaphone.fm/adchoices Sun, 04 Aug 2024 16:00:00 -0000 "We want to become a dominant figure in wound care" - Aroa Biosurgery (ASX:ARX) full Stockhead In today's episode, Nadine speaks to James Agnew, CFO of Aroa Biosurgery (ASX:ARX) to discuss New Zealand's history of medical advancements and how Aroa is looking to become a world leader in wound care. After listing in 2020, Aroa is building from the original discoveries made by Dr. Brian Ward, using the forestomach of sheep to create a tissue scaffold assisting with chronic wound care, hernia repair and breast reconstruction among other conditions. James also gives us details on the company's current financial position and what the next 3-5 years looks like for growth. Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to James Agnew, CFO of Aroa Biosurgery (ASX:ARX) to discuss New Zealand's history of medical advancements and how Aroa is looking to become a world leader in wound care. After listing in 2020, Aroa is building from the original discoveries made by Dr. Brian Ward, using the forestomach of sheep to create a tissue scaffold assisting with chronic wound care, hernia repair and breast reconstruction among other conditions. James also gives us details on the company's current financial position and what the next 3-5 years looks like for growth.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1055 no "Truly life-changing technology" - Optiscan (ASX:OIL) | Vital Signs In today's episode, Nadine speaks to Dr Camile Farah, CEO of Optiscan (ASX:OIL) to discuss the fascinating history of the real time frozen section, breakthrough discoveries in pathology and how Optiscan is partnering with the world-renowned Mayo Clinic to develop technologies for safer and less intrusive procedures. Learn more about your ad choices. Visit megaphone.fm/adchoices Thu, 11 Jul 2024 01:53:00 -0000 "Truly life-changing technology" - Optiscan (ASX:OIL) full Stockhead In today's episode, Nadine speaks to Dr Camile Farah, CEO of Optiscan (ASX:OIL) to discuss the fascinating history of the real time frozen section, breakthrough discoveries in pathology and how Optiscan is partnering with the world-renowned Mayo Clinic to develop technologies for safer and less intrusive procedures. Learn more about your ad choices. Visit megaphone.fm/adchoices In today's episode, Nadine speaks to Dr Camile Farah, CEO of Optiscan (ASX:OIL) to discuss the fascinating history of the real time frozen section, breakthrough discoveries in pathology and how Optiscan is partnering with the world-renowned Mayo Clinic to develop technologies for safer and less intrusive procedures.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1575 no